Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia

Annals of Hematology

Volumn 93, Issue 11, 2014, Pages 1839-1843

  Aldoss, Ibrahin ^a   Mark, Lisa ^a   Vrona, Janice ^a   Ramezani, Laleh ^a   Weitz, Ilene ^a   Mohrbacher, Ann M ^a   Douer, Dan ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AML; Arsenic trioxide; Ascorbic acid

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; ORGANOARSENIC DERIVATIVE; OXIDE;

ADULT; AGED; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARSENICALS; ASCORBIC ACID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OXIDES; TREATMENT OUTCOME;

EID: 84921793755     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2124-y     Document Type: Article

References (25)

1. Shigeno K, Naito K, Sahara N et al (2005) Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 82(3):224–229
2. Soignet SL, Frankel SR, Douer D et al (2011) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852–3860
3. Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121
4. Mathews V, George B, Lakshmi KM et al (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107:2627–2632
5. Douer D, Tallman MS (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396–2410
6. Zhang W, Ohnishi K, Shigeno K et al (1998) The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 12:1383–1391
7. Akao Y, Mizoguchi H, Kojima S et al (1998) Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Hematol 102:1055–1060
8. Akao Y, Nakagawa Y, Akiyama K (1999) Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455:59–62
9. Perkins C, Kim CN, Fang G, Bhalla KN (2000) Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95:1014–1022
10. Cai X, Shen YL, Zhu Q et al (2000) Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14:262–270
11. Dai J, Weinberg RS, Waxman S et al (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268–277
12. Jing Y, Dai J, Chalmers-Redman RME et al (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102–2111
13. Parmar S, Rundhaugen LM, Boehlke L et al (2004) Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 28:909–919
14. Schiller GJ, Slack J, Hainsworth JD et al (2006) Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 24:2456–2464
15. Vey N, Bosly A, Guerci A et al (2006) Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 24:2465–2471
16. Lee TC, Wei ML, Chang WJ et al (1989) Elevation of glutathione levels and glutathione S-transferase activity in arsenic-resistant Chinese hamster ovary cells. In Vitro Cell Dev Biol 25:442–448
17. Ochi T, Kaise T, Oya-Ohta Y (1994) Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in cultured BALB/c 3T3 cells. Experientia 50:115–120
18. Ochi T, Nakajima F, Sakurai T et al (1996) Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione. Arch Toxicol 70:815–821
19. Grad JM, Bahlis NJ, Reis I et al (2001) Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98:805–813
20. Sakagami H, Satoh K (1997) Modulating factors of radical intensity and cytotoxic activity of ascorbate. Anticancer Res 17:3513–3520
21. Vera JC, Rivas CI, Fischbarg J, Golde DW (1993) Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 364:79–82
22. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I et al (2002) Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/ refractory multiple myeloma. Clin Cancer Res 8:3658–3668
23. Roboz GJ, Ritchie EK, Curcio T et al (2008) Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 113:2504–2511
24. Burnett AK, Milligan D, Prentice AG et al (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114–1124
25. Burnett AK, Hills RK, Hunter A et al (2011) The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 25:1122–1127